1
|
Immunomodulatory Potential of Non-Classical HLA-G in Infections including COVID-19 and Parasitic Diseases. Biomolecules 2022; 12:biom12020257. [PMID: 35204759 PMCID: PMC8961671 DOI: 10.3390/biom12020257] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2021] [Revised: 01/23/2022] [Accepted: 01/31/2022] [Indexed: 02/04/2023] Open
Abstract
Human Leukocyte Antigen-G (HLA-G), a polymorphic non-classical HLA (HLA-Ib) with immune-regulatory properties in cancers and infectious diseases, presents both membrane-bound and soluble (sHLA-G) isoforms. Polymorphism has implications in host responses to pathogen infections and in pathogenesis. Differential expression patterns of HLA-G/sHLA-G or its polymorphism seem to be related to different pathological conditions, potentially acting as a disease progression biomarker. Pathogen antigens might be involved in the regulation of both membrane-bound and sHLA-G levels and impact immune responses during co-infections. The upregulation of HLA-G in viral and bacterial infections induce tolerance to infection. Recently, sHLA-G was found useful to identify the prognosis of Coronavirus disease 2019 (COVID-19) among patients and it was observed that the high levels of sHLA-G are associated with worse prognosis. The use of pathogens, such as Plasmodium falciparum, as immune modulators for other infections could be extended for the modulation of membrane-bound HLA-G in COVID-19-infected tissues. Overall, such information might open new avenues concerning the effect of some pathogens such as parasites in decreasing the expression level of HLA-G to restrict pathogenesis in some infections or to influence the immune responses after vaccination among others.
Collapse
|
2
|
Abdallah F, Coindre S, Gardet M, Meurisse F, Naji A, Suganuma N, Abi-Rached L, Lambotte O, Favier B. Leukocyte Immunoglobulin-Like Receptors in Regulating the Immune Response in Infectious Diseases: A Window of Opportunity to Pathogen Persistence and a Sound Target in Therapeutics. Front Immunol 2021; 12:717998. [PMID: 34594332 PMCID: PMC8478328 DOI: 10.3389/fimmu.2021.717998] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2021] [Accepted: 08/25/2021] [Indexed: 12/19/2022] Open
Abstract
Immunoregulatory receptors are essential for orchestrating an immune response as well as appropriate inflammation in infectious and non-communicable diseases. Among them, leukocyte immunoglobulin-like receptors (LILRs) consist of activating and inhibitory receptors that play an important role in regulating immune responses modulating the course of disease progression. On the one hand, inhibitory LILRs constitute a safe-guard system that mitigates the inflammatory response, allowing a prompt return to immune homeostasis. On the other hand, because of their unique capacity to attenuate immune responses, pathogens use inhibitory LILRs to evade immune recognition, thus facilitating their persistence within the host. Conversely, the engagement of activating LILRs triggers immune responses and the production of inflammatory mediators to fight microbes. However, their heightened activation could lead to an exacerbated immune response and persistent inflammation with major consequences on disease outcome and autoimmune disorders. Here, we review the genetic organisation, structure and ligands of LILRs as well as their role in regulating the immune response and inflammation. We also discuss the LILR-based strategies that pathogens use to evade immune responses. A better understanding of the contribution of LILRs to host-pathogen interactions is essential to define appropriate treatments to counteract the severity and/or persistence of pathogens in acute and chronic infectious diseases lacking efficient treatments.
Collapse
Affiliation(s)
- Florence Abdallah
- Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses, France
| | - Sixtine Coindre
- Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses, France
| | - Margaux Gardet
- Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses, France
| | - Florian Meurisse
- Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses, France
| | - Abderrahim Naji
- Department of Environmental Medicine, Cooperative Medicine Unit, Research and Education Faculty, Medicine Science Cluster, Kochi Medical School, Kochi University, Nankoku-City, Japan
| | - Narufumi Suganuma
- Department of Environmental Medicine, Cooperative Medicine Unit, Research and Education Faculty, Medicine Science Cluster, Kochi Medical School, Kochi University, Nankoku-City, Japan
| | - Laurent Abi-Rached
- Aix-Marseille University, IRD, APHM, MEPHI, IHU Mediterranean Infection, SNC5039 CNRS, Marseille, France.,SNC5039 CNRS, Marseille, France
| | - Olivier Lambotte
- Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses, France.,Public-Hospital Assistance of Paris, Department of Internal Medicine and Clinical Immunology, Paris-Saclay University Hospital Group, Bicêtre Hospital, Le Kremlin-Bicêtre, France
| | - Benoit Favier
- Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses, France
| |
Collapse
|
3
|
Alvar J, Alves F, Bucheton B, Burrows L, Büscher P, Carrillo E, Felger I, Hübner MP, Moreno J, Pinazo MJ, Ribeiro I, Sosa-Estani S, Specht S, Tarral A, Wourgaft NS, Bilbe G. Implications of asymptomatic infection for the natural history of selected parasitic tropical diseases. Semin Immunopathol 2020; 42:231-246. [PMID: 32189034 PMCID: PMC7299918 DOI: 10.1007/s00281-020-00796-y] [Citation(s) in RCA: 29] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2019] [Accepted: 03/03/2020] [Indexed: 12/18/2022]
Abstract
Progress has been made in the control or elimination of tropical diseases, with a significant reduction of incidence. However, there is a risk of re-emergence if the factors fueling transmission are not dealt with. Although it is essential to understand these underlying factors for each disease, asymptomatic carriers are a common element that may promote resurgence; their impact in terms of proportion in the population and role in transmission needs to be determined. In this paper, we review the current evidence on whether or not to treat asymptomatic carriers given the relevance of their role in the transmission of a specific disease, the efficacy and toxicity of existing drugs, the Public Health interest, and the benefit at an individual level, for example, in Chagas disease, to prevent irreversible organ damage. In the absence of other control tools such as vaccines, there is a need for safer drugs with good risk/benefit profiles in order to change the paradigm so that it addresses the complete infectious process beyond manifest disease to include treatment of non-symptomatic infected persons.
Collapse
Affiliation(s)
- Jorge Alvar
- Drugs for Neglected Diseases initiative, Geneva, Switzerland.
| | - Fabiana Alves
- Drugs for Neglected Diseases initiative, Geneva, Switzerland
| | - Bruno Bucheton
- Institut de Recherche pour le Développement, Université de Montpellier, Montpellier, France
| | - Louise Burrows
- Drugs for Neglected Diseases initiative, Geneva, Switzerland
| | | | - Eugenia Carrillo
- WHO Collaborating Cenre for Leishmaniasis, Instituto de Sakud Carlos III, Madrid, Spain
| | - Ingrid Felger
- Swiss Tropical and Public Health Institute, Basel, Switzerland
| | - Marc P Hübner
- Institute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Bonn, Germany
| | - Javier Moreno
- WHO Collaborating Cenre for Leishmaniasis, Instituto de Sakud Carlos III, Madrid, Spain
| | | | - Isabela Ribeiro
- Drugs for Neglected Diseases initiative, Geneva, Switzerland
| | - Sergio Sosa-Estani
- Drugs for Neglected Diseases initiative, Centro de Investigación de Epidemiología y Salud Pública (CIESP-IECS), CONICET, Buenos Aires, Argentina
| | - Sabine Specht
- Drugs for Neglected Diseases initiative, Geneva, Switzerland
| | - Antoine Tarral
- Drugs for Neglected Diseases initiative, Geneva, Switzerland
| | | | - Graeme Bilbe
- Drugs for Neglected Diseases initiative, Geneva, Switzerland
| |
Collapse
|
4
|
Dama E, Camara O, Kaba D, Koffi M, Camara M, Compaoré C, Ilboudo H, Courtin F, Kaboré J, N'Gouan EK, Büscher P, Lejon V, Bucheton B, Jamonneau V. Immune trypanolysis test as a promising bioassay to monitor the elimination of gambiense human African trypanosomiasis. ACTA ACUST UNITED AC 2019; 26:68. [PMID: 31755862 PMCID: PMC6873819 DOI: 10.1051/parasite/2019066] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2019] [Accepted: 10/30/2019] [Indexed: 01/07/2023]
Abstract
The World Health Organization (WHO) has set the goal of gambiense-Human African trypanosomiasis (HAT) elimination as a public health problem for 2020 and interruption of transmission in humans for 2030. In this context, it is crucial to monitor progress towards these targets using accurate tools to assess the level of transmission in a given area. The aim of this study was to investigate the relevance of the immune trypanolysis test (TL) as a population-based bioassay to evaluate Trypanosoma brucei gambiense transmission in various epidemiological contexts. Significant correlations were observed between HAT endemicity levels and the percentage of TL-positive individuals in the population. TL therefore appears to be a suitable population-based biomarker of the intensity of transmission. In addition to being used as a tool to assess the HAT status at an individual level, assessing the proportion of TL positive individuals in the population appears as a promising and easy alternative to monitor the elimination of gambiense HAT in a given area.
Collapse
Affiliation(s)
- Emilie Dama
- Centre International de Recherche-Développement sur l'Elevage en zones Subhumides (CIRDES), Unité de recherches sur les maladies à vecteurs et biodiversité, 01 BP 454 Bobo-Dioulasso 01, Burkina Faso - Université Nazi Boni, Bobo-Dioulasso, 01 BP 1091 Bobo-Dioulasso, Burkina Faso
| | - Oumou Camara
- Programme National de Lutte contre la Trypanosomose Humaine Africaine, BP 851, Conakry, Guinée
| | - Dramane Kaba
- Institut Pierre Richet, Unité de Recherche « Trypanosomoses », 01 BP 1500, Bouaké, Côte d'Ivoire
| | - Mathurin Koffi
- Université Jean Lorougnon Guédé, Laboratoire de biodiversité et Gestion durable des écosystèmes tropicaux, Unité de Recherche en Génétique et Epidémiologie moléculaire, BP 150 Daloa, Côte d'Ivoire
| | - Mamadou Camara
- Programme National de Lutte contre la Trypanosomose Humaine Africaine, BP 851, Conakry, Guinée
| | - Charlie Compaoré
- Centre International de Recherche-Développement sur l'Elevage en zones Subhumides (CIRDES), Unité de recherches sur les maladies à vecteurs et biodiversité, 01 BP 454 Bobo-Dioulasso 01, Burkina Faso
| | - Hamidou Ilboudo
- Institut de Recherche en Sciences de la Santé (IRSS), Unité de Recherche Clinique de Nanoro (URCN), 11 BP 218 Ouagadougou CMS 11, Burkina Faso
| | - Fabrice Courtin
- Institut Pierre Richet, Unité de Recherche « Trypanosomoses », 01 BP 1500, Bouaké, Côte d'Ivoire - Institut de Recherche pour le Développement (IRD), UMR INTERTRYP IRD-CIRAD, Université de Montpellier, TA A-17/G, Campus International de Baillarguet, F-34398 Montpellier, France
| | - Jacques Kaboré
- Centre International de Recherche-Développement sur l'Elevage en zones Subhumides (CIRDES), Unité de recherches sur les maladies à vecteurs et biodiversité, 01 BP 454 Bobo-Dioulasso 01, Burkina Faso - Université Nazi Boni, Bobo-Dioulasso, 01 BP 1091 Bobo-Dioulasso, Burkina Faso
| | | | - Philippe Büscher
- Institute of Tropical Medicine, Department of Biomedical Sciences, Nationalestraat 155, 2000 Antwerp, Belgium
| | - Veerle Lejon
- Institut de Recherche pour le Développement (IRD), UMR INTERTRYP IRD-CIRAD, Université de Montpellier, TA A-17/G, Campus International de Baillarguet, F-34398 Montpellier, France
| | - Bruno Bucheton
- Programme National de Lutte contre la Trypanosomose Humaine Africaine, BP 851, Conakry, Guinée - Institut de Recherche pour le Développement (IRD), UMR INTERTRYP IRD-CIRAD, Université de Montpellier, TA A-17/G, Campus International de Baillarguet, F-34398 Montpellier, France
| | - Vincent Jamonneau
- Institut Pierre Richet, Unité de Recherche « Trypanosomoses », 01 BP 1500, Bouaké, Côte d'Ivoire - Institut de Recherche pour le Développement (IRD), UMR INTERTRYP IRD-CIRAD, Université de Montpellier, TA A-17/G, Campus International de Baillarguet, F-34398 Montpellier, France
| |
Collapse
|
5
|
Kaboré JW, Camara O, Ilboudo H, Capewell P, Clucas C, Cooper A, Kaboré J, Camara M, Jamonneau V, Hertz-Fowler C, Bélem AMG, Matovu E, Macleod A, Sidibé I, Noyes H, Bucheton B. Macrophage migrating inhibitory factor expression is associated with Trypanosoma brucei gambiense infection and is controlled by trans-acting expression quantitative trait loci in the Guinean population. INFECTION GENETICS AND EVOLUTION 2019; 71:108-115. [PMID: 30914286 DOI: 10.1016/j.meegid.2019.03.021] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/04/2018] [Revised: 03/21/2019] [Accepted: 03/22/2019] [Indexed: 02/06/2023]
Abstract
Infection by Trypanosoma brucei gambiense is characterized by a wide array of clinical outcomes, ranging from asymptomatic to acute disease and even spontaneous cure. In this study, we investigated the association between macrophage migrating inhibitory factor (MIF), an important pro-inflammatory cytokine that plays a central role in both innate and acquired immunity, and disease outcome during T. b. gambiense infection. A comparative expression analysis of patients, individuals with latent infection and controls found that MIF had significantly higher expression in patients (n = 141; 1.25 ± 0.07; p < .0001) and latent infections (n = 25; 1.23 ± 0.13; p = .0005) relative to controls (n = 46; 0.94 ± 0.11). Furthermore, expression decreased significantly after treatment (patients before treatment n = 33; 1.40 ± 0.18 versus patients after treatment n = 33; 0.99 ± 0.10, p = .0001). We conducted a genome wide eQTL analysis on 29 controls, 128 cases and 15 latently infected individuals for whom expression and genotype data were both available. Four loci, including one containing the chemokine CXCL13, were found to associate with MIF expression. Genes at these loci are candidate regulators of increased expression of MIF after infection. Our study is the first data demonstrating that MIF expression is elevated in T. b. gambiense-infected human hosts but does not appear to contribute to pathology.
Collapse
Affiliation(s)
- Justin Windingoudi Kaboré
- Centre International de Recherche-Développement sur l'Élevage en zone Subhumide (CIRDES), Unité des Maladies à Vecteurs et Biodiversités (UMaVeB), Bobo-Dioulasso, Burkina Faso
| | - Oumou Camara
- Ministère de la Santé et de l'Hygiène Publique, Programme National de Lutte contre la Trypanosomiase Humaine Africaine (PNLTHA), Conakry, Guinea
| | - Hamidou Ilboudo
- Institut de Recherche en Sciences de la Santé (IRSS), Unité de Recherche Clinique de Nanoro (URCN), Nanoro, Burkina Faso
| | - Paul Capewell
- University of Glasgow, Wellcome Trust Centre for Molecular Parasitology, Glasgow, United Kingdom
| | - Caroline Clucas
- University of Glasgow, Wellcome Trust Centre for Molecular Parasitology, Glasgow, United Kingdom
| | - Anneli Cooper
- University of Glasgow, Wellcome Trust Centre for Molecular Parasitology, Glasgow, United Kingdom
| | - Jacques Kaboré
- Centre International de Recherche-Développement sur l'Élevage en zone Subhumide (CIRDES), Unité des Maladies à Vecteurs et Biodiversités (UMaVeB), Bobo-Dioulasso, Burkina Faso; Université Nazi Boni (UNB), Bobo-Dioulasso, Burkina Faso
| | - Mamadou Camara
- Ministère de la Santé et de l'Hygiène Publique, Programme National de Lutte contre la Trypanosomiase Humaine Africaine (PNLTHA), Conakry, Guinea
| | - Vincent Jamonneau
- Institut de Recherche pour le Développement (IRD), UMR IRD-CIRAD 177 INTERTRYP, Montpellier, France
| | | | | | - Enock Matovu
- Makerere University, College of Veterinary Medicine Animal Resources and Biosecurity, Kampala, Uganda
| | - Annette Macleod
- University of Glasgow, Wellcome Trust Centre for Molecular Parasitology, Glasgow, United Kingdom
| | - Issa Sidibé
- Centre International de Recherche-Développement sur l'Élevage en zone Subhumide (CIRDES), Unité des Maladies à Vecteurs et Biodiversités (UMaVeB), Bobo-Dioulasso, Burkina Faso
| | - Harry Noyes
- University of Liverpool, Centre for Genomic Research, Liverpool, United Kingdom
| | - Bruno Bucheton
- Ministère de la Santé et de l'Hygiène Publique, Programme National de Lutte contre la Trypanosomiase Humaine Africaine (PNLTHA), Conakry, Guinea; Institut de Recherche pour le Développement (IRD), UMR IRD-CIRAD 177 INTERTRYP, Montpellier, France.
| | | |
Collapse
|
6
|
Ofon E, Noyes H, Ebo’o Eyanga V, Njiokou F, Koffi M, Fogue P, Hertz-Fowler C, MacLeod A, Matovu E, Simo G. Association between IL1 gene polymorphism and human African trypanosomiasis in populations of sleeping sickness foci of southern Cameroon. PLoS Negl Trop Dis 2019; 13:e0007283. [PMID: 30908482 PMCID: PMC6448947 DOI: 10.1371/journal.pntd.0007283] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2018] [Revised: 04/04/2019] [Accepted: 03/07/2019] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND Human African Trypanosomiasis (HAT) is a neglected tropical disease caused by infections due to Trypanosoma brucei subspecies. In addition to the well-established environmental and behavioural risks of becoming infected, there is evidence for a genetic component to the response to trypanosome infection. We undertook a candidate gene case-control study to investigate genetic associations further. METHODOLOGY We genotyped one polymorphism in each of seven genes (IL1A, IL1RN, IL4RN, IL6, HP, HPR, and HLA-G) in 73 cases and 250 controls collected from 19 ethno-linguistic subgroups stratified into three major ethno-linguistic groups, 2 pooled ethno-linguistic groups and 11 ethno-linguistic subgroups from three Cameroonian HAT foci. The seven polymorphic loci tested consisted of three SNPs, three variable numbers of tandem repeat (VNTR) and one INDEL. RESULTS We found that the genotype (TT) and minor allele (T) of IL1A gene as well as the genotype 1A3A of IL1RN were associated with an increased risk of getting Trypanosoma brucei gambiense and develop HAT when all data were analysed together and also when stratified by the three major ethno-linguistic groups, 2 pooled ethno-linguistic subgroups and 11 ethno-linguistic subgroups. CONCLUSION This study revealed that one SNP rs1800794 of IL1A and one VNTR rs2234663 of IL1RN were associated with the increased risk to be infected by Trypanosoma brucei gambiense and develop sleeping sickness in southern Cameroon. The minor allele T and the genotype TT of SNP rs1800794 in IL1A as well as the genotype 1A3A of IL1RN rs2234663 VNTR seem to increase the risk of getting Trypanosoma brucei gambiense infections and develop sleeping sickness in southern Cameroon.
Collapse
Affiliation(s)
- Elvis Ofon
- Molecular Parasitology and Entomology Unit, Department of Biochemistry, Faculty of Science, University of Dschang, Dschang, Cameroon
| | - Harry Noyes
- Centre for Genomic Research, University of Liverpool, Liverpool, United Kingdom
| | - Vincent Ebo’o Eyanga
- MINSANTE, Divisional Centre for Diseases, PNLTHA, Ministry of Public Health, Yaoundé, Cameroon
| | - Flobert Njiokou
- Laboratory of Molecular Biology, Department of Animal Biology, Faculty of Science, University of Yaoundé I, Yaoundé, Cameroon
| | - Mathurin Koffi
- Université Jean Lorougnon Guédé (UJLoG), UFR Environnement-Santé, Laboratoire des Interactions Hôte- Microorganismes-Environnement et Evolution (LIHME) Daloa, Côte d’Ivoire
| | - Pythagore Fogue
- Molecular Parasitology and Entomology Unit, Department of Biochemistry, Faculty of Science, University of Dschang, Dschang, Cameroon
| | | | - Annette MacLeod
- Wellcome Centre for Molecular Parasitology, University Place, Glasgow, United Kingdom
| | - Enock Matovu
- College of Veterinary Medicine, Animal Resources and Bio-security, Makerere University, Kampala, Uganda
| | - Gustave Simo
- Molecular Parasitology and Entomology Unit, Department of Biochemistry, Faculty of Science, University of Dschang, Dschang, Cameroon
| | | |
Collapse
|
7
|
Dias FC, Bertol BC, Poras I, Souto BM, Mendes-Junior CT, Castelli EC, Gineau L, Sabbagh A, Rouas-Freiss N, Carosella ED, Donadi EA, Moreau P. The genetic diversity within the 1.4 kb HLA-G 5' upstream regulatory region moderately impacts on cellular microenvironment responses. Sci Rep 2018; 8:5652. [PMID: 29618829 PMCID: PMC5884815 DOI: 10.1038/s41598-018-24009-7] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2017] [Accepted: 03/15/2018] [Indexed: 12/21/2022] Open
Abstract
The HLA-G 5'URR extending 1.4 kb from the ATG presents a unique set of regulatory elements among HLA genes. Several variable sites have been described that coincide with or are close to these elements, thus HLA-G 5'URR polymorphism might influence the HLA-G expression level. We cloned the ten most frequent HLA-G 5'URR haplotypes to evaluate their activity on a luciferase reporter gene in HLA-G+ cell lines (JEG-3/choriocarcinoma and FON+/melanoma). We also investigated associations between the plasma HLA-G (sHLA-G) levels and the HLA-G 5'URR variability in 157 healthy individuals. Cell lines were transfected with pGL3-Basic vector constructions containing HLA-G 5'URR sequences. The G010101a (in JEG-3) and G010101b (in FON+) haplotypes exhibited higher promoter activity, whereas the G010101d (in JEG-3) and G010102a (in FON+) haplotypes exhibited lower promoter activity. In the presence of HLA-G inducers (interferon-β and progesterone) or repressors (cyclopamine) HLA-G promoter activity was modulated, but certain haplotypes exhibited differential responses. No strict association was observed between plasma sHLA-G levels and the 5'URR haplotypes or genotypes; however, the G010101b haplotype was underrepresented among HLA-G-negative plasmas. Therefore, the HLA-G 5'URR polymorphism may have an impact on the modulation of HLA-G gene expression, but alone provides a limited predictive value for sHLA-G levels in vivo.
Collapse
Affiliation(s)
- Fabrício C Dias
- Department of Medicine, Division of Clinical Immunology, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, ZIP Code 14.049-900, Brazil.,Commissariat à l'Energie Atomique et aux Energies Alternatives, Direction de la Recherche Fondamentale, Institut de Biologie François Jacob, Service de Recherches en Hémato-Immunologie, Hôpital Saint-Louis, Paris, ZIP code 75010, France.,Université Paris-Diderot, Sorbonne Paris-Cité, UMR_E5, Institut Universitaire d'Hématologie, Hôpital Saint-Louis, Paris, ZIP code 75010, France
| | - Bruna C Bertol
- Department of Biochemistry and Immunology, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, ZIP Code 14.049-900, Brazil
| | - Isabelle Poras
- Commissariat à l'Energie Atomique et aux Energies Alternatives, Direction de la Recherche Fondamentale, Institut de Biologie François Jacob, Service de Recherches en Hémato-Immunologie, Hôpital Saint-Louis, Paris, ZIP code 75010, France.,Université Paris-Diderot, Sorbonne Paris-Cité, UMR_E5, Institut Universitaire d'Hématologie, Hôpital Saint-Louis, Paris, ZIP code 75010, France
| | - Bruno M Souto
- Department of Medicine, Division of Clinical Immunology, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, ZIP Code 14.049-900, Brazil
| | - Celso T Mendes-Junior
- Departamento de Química, Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, ZIP Code 14.049-900, Brazil
| | - Erick C Castelli
- São Paulo State University (UNESP), Department of Pathology, School of Medicine, Botucatu, State of São, Paulo, ZIP Code 18.618-687, Brazil
| | - Laure Gineau
- UMR 216-MERIT, Institut de Recherche pour le Développement, Faculté de Pharmacie de Paris - Université Paris Descartes, COMUE Sorbonne Paris-Cité, Paris, ZIP Code 75006, France
| | - Audrey Sabbagh
- UMR 216-MERIT, Institut de Recherche pour le Développement, Faculté de Pharmacie de Paris - Université Paris Descartes, COMUE Sorbonne Paris-Cité, Paris, ZIP Code 75006, France
| | - Nathalie Rouas-Freiss
- Commissariat à l'Energie Atomique et aux Energies Alternatives, Direction de la Recherche Fondamentale, Institut de Biologie François Jacob, Service de Recherches en Hémato-Immunologie, Hôpital Saint-Louis, Paris, ZIP code 75010, France.,Université Paris-Diderot, Sorbonne Paris-Cité, UMR_E5, Institut Universitaire d'Hématologie, Hôpital Saint-Louis, Paris, ZIP code 75010, France
| | - Edgardo D Carosella
- Commissariat à l'Energie Atomique et aux Energies Alternatives, Direction de la Recherche Fondamentale, Institut de Biologie François Jacob, Service de Recherches en Hémato-Immunologie, Hôpital Saint-Louis, Paris, ZIP code 75010, France.,Université Paris-Diderot, Sorbonne Paris-Cité, UMR_E5, Institut Universitaire d'Hématologie, Hôpital Saint-Louis, Paris, ZIP code 75010, France
| | - Eduardo A Donadi
- Department of Medicine, Division of Clinical Immunology, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, ZIP Code 14.049-900, Brazil.,Department of Biochemistry and Immunology, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, ZIP Code 14.049-900, Brazil
| | - Philippe Moreau
- Commissariat à l'Energie Atomique et aux Energies Alternatives, Direction de la Recherche Fondamentale, Institut de Biologie François Jacob, Service de Recherches en Hémato-Immunologie, Hôpital Saint-Louis, Paris, ZIP code 75010, France. .,Université Paris-Diderot, Sorbonne Paris-Cité, UMR_E5, Institut Universitaire d'Hématologie, Hôpital Saint-Louis, Paris, ZIP code 75010, France.
| |
Collapse
|
8
|
Büscher P, Bart JM, Boelaert M, Bucheton B, Cecchi G, Chitnis N, Courtin D, Figueiredo LM, Franco JR, Grébaut P, Hasker E, Ilboudo H, Jamonneau V, Koffi M, Lejon V, MacLeod A, Masumu J, Matovu E, Mattioli R, Noyes H, Picado A, Rock KS, Rotureau B, Simo G, Thévenon S, Trindade S, Truc P, Van Reet N. Do Cryptic Reservoirs Threaten Gambiense-Sleeping Sickness Elimination? Trends Parasitol 2018; 34:197-207. [PMID: 29396200 PMCID: PMC5840517 DOI: 10.1016/j.pt.2017.11.008] [Citation(s) in RCA: 103] [Impact Index Per Article: 17.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2017] [Revised: 11/18/2017] [Accepted: 11/27/2017] [Indexed: 12/22/2022]
Abstract
Trypanosoma brucei gambiense causes human African trypanosomiasis (HAT). Between 1990 and 2015, almost 440000 cases were reported. Large-scale screening of populations at risk, drug donations, and efforts by national and international stakeholders have brought the epidemic under control with <2200 cases in 2016. The World Health Organization (WHO) has set the goals of gambiense-HAT elimination as a public health problem for 2020, and of interruption of transmission to humans for 2030. Latent human infections and possible animal reservoirs may challenge these goals. It remains largely unknown whether, and to what extend, they have an impact on gambiense-HAT transmission. We argue that a better understanding of the contribution of human and putative animal reservoirs to gambiense-HAT epidemiology is mandatory to inform elimination strategies.
Collapse
Affiliation(s)
- Philippe Büscher
- Department of Biomedical Sciences, Institute of Tropical Medicine, Nationalestraat 155, 2000 Antwerp, Belgium.
| | - Jean-Mathieu Bart
- INTERTRYP, IRD, CIRAD, Univ Montpellier, Montpellier, France; Centro Nacional de Medicina Tropical, Instituto de Salud Carlos III, Calle Sinesio Delgado 4, 28029 Madrid, Spain
| | - Marleen Boelaert
- Department of Public Health, Institute of Tropical Medicine, Nationalestraat 155, 2000 Antwerp, Belgium
| | - Bruno Bucheton
- INTERTRYP, IRD, CIRAD, Univ Montpellier, Montpellier, France
| | - Giuliano Cecchi
- Sub-regional Office for Eastern Africa, Food and Agriculture Organization of the United Nations, CMC Road, Bole Sub City, Kebele 12/13, P O Box 5536, Addis Ababa, Ethiopia
| | - Nakul Chitnis
- Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Socinstrasse 57, Postfach, 4002 Basel, Switzerland; University of Basel, Switzerland
| | - David Courtin
- Université Paris Descartes, Institut de Recherche pour le Développement, Unité MERIT, Mère et enfant face aux infections tropicales, 4 avenue de l'Observatoire, 75006 Paris, France
| | - Luisa M Figueiredo
- Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Avenida Prof Egas Moniz, 1649-028 Lisboa, Portugal
| | - José-Ramon Franco
- Control of Neglected Tropical Diseases, Innovative and Intensified Disease Management, World Health Organization, Via Appia 20, 1202 Geneva, Switzerland
| | - Pascal Grébaut
- INTERTRYP, IRD, CIRAD, Univ Montpellier, Montpellier, France
| | - Epco Hasker
- Department of Public Health, Institute of Tropical Medicine, Nationalestraat 155, 2000 Antwerp, Belgium
| | - Hamidou Ilboudo
- Institut de Recherche sur les Bases Biologiques de la Lutte Intégrée, Centre International de Recherche-Développement sur l'Élevage en zone Subhumide, 01 BP 454 Bobo-Dioulasso 01, Burkina Faso
| | | | - Mathurin Koffi
- Université Jean Lorougnon Guédé, BP 150 Daloa, Côte d'Ivoire
| | - Veerle Lejon
- INTERTRYP, IRD, CIRAD, Univ Montpellier, Montpellier, France
| | - Annette MacLeod
- Institute of Biodiversity, Animal Health and Comparative Medicine, University of Glasgow, Henry Wellcome Building, 464 Bearsden Road, Glasgow, UK
| | - Justin Masumu
- Département de Parasitologie, Institut National de Recherche Biomédicale, Avenue de la Démocratie, BP 1197 Kinshasa 1, République Démocratique du Congo
| | - Enock Matovu
- College of Veterinary Medicine, Animal Resources and Biosecurity, Makerere University, P O Box 7062 Kampala, Uganda
| | - Raffaele Mattioli
- Animal Production and Health Division, Food and Agriculture Organization of the United Nations, Viale delle Terme di Caracalla, 00153 Rome, Italy
| | - Harry Noyes
- Institute of Integrative Biology, University of Liverpool, Liverpool L69 7ZB, UK
| | - Albert Picado
- Foundation for Innovative New Diagnostics, 9 Chemin des Mines, 1202 Geneva, Switzerland
| | - Kat S Rock
- Zeeman Institute for Systems Biology & Infectious Disease Research, University of Warwick, Gibbet Hill Road, Coventry CV4 7AL, UK
| | - Brice Rotureau
- Trypanosome Transmission Group, Trypanosome Cell Biology Unit, INSERM U1201 and Department of Parasites and Insect Vectors, Institut Pasteur, 25, rue du Docteur Roux, 75015 Paris, France
| | - Gustave Simo
- Department of Biochemistry, Faculty of Science, University of Dschang, P O Box 67 Dschang, Cameroon
| | - Sophie Thévenon
- INTERTRYP, IRD, CIRAD, Univ Montpellier, Montpellier, France; CIRAD, INTERTRYP, Montpellier, France
| | - Sandra Trindade
- Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Avenida Prof Egas Moniz, 1649-028 Lisboa, Portugal
| | - Philippe Truc
- INTERTRYP, IRD, CIRAD, Univ Montpellier, Montpellier, France
| | - Nick Van Reet
- Department of Biomedical Sciences, Institute of Tropical Medicine, Nationalestraat 155, 2000 Antwerp, Belgium
| |
Collapse
|